Article

Plasma and Muscle Myostatin in Relation to Type 2 Diabetes

University of Las Palmas de Gran Canaria, Spain
PLoS ONE (Impact Factor: 3.53). 05/2012; 7(5):e37236. DOI: 10.1371/journal.pone.0037236
Source: PubMed

ABSTRACT Myostatin is a secreted growth factor expressed in skeletal muscle tissue, which negatively regulates skeletal muscle mass. Recent animal studies suggest a role for myostatin in insulin resistance. We evaluated the possible metabolic role of myostatin in patients with type 2 diabetes and healthy controls.
76 patients with type 2 diabetes and 92 control subjects were included in the study. They were matched for age, gender and BMI. Plasma samples and biopsies from the vastus lateralis muscle were obtained to assess plasma myostatin and expression of myostatin in skeletal muscle.
Patients with type 2 diabetes had higher fasting glucose (8.9 versus 5.1 mmol/L, P<0.001), plasma insulin (68.2 versus 47.2 pmol/L, P<0.002) and HOMA2-IR (1.6 versus 0.9, P<0.0001) when compared to controls. Patients with type 2 diabetes had 1.4 (P<0.01) higher levels of muscle myostatin mRNA content than the control subjects. Plasma myostatin concentrations did not differ between patients with type 2 diabetes and controls. In healthy controls, muscle myostatin mRNA correlated with HOMA2-IR (r = 0.30, P<0.01), plasma IL-6 (r = 0.34, P<0.05) and VO2 max (r = -0.26, P<0.05), however, no correlations were observed in patients with type 2 diabetes.
This study supports the idea that myostatin may have a negative effect on metabolism. However, the metabolic effect of myostatin appears to be overruled by other factors in patients with type 2 diabetes.

Download full-text

Full-text

Available from: Christian Philip Philip Fischer, Aug 07, 2015
0 Followers
 · 
232 Views
  • Source
    • "Yet, no in vivo data exist on fstl3 binding to activin A. Global knockout of myostatin or pharmacological blockade of the myostatin receptor, ActRIIB, protects against high-fat (HF) diet-induced obesity [12] [13] [14]. In continuation, increased plasma and muscle myostatin levels are associated with obesity and insulin resistance in humans [15] [16] [17]. Similar to myostatin, circulating activin A levels are associated with insulin resistance in humans [18] and loss of activin A in mice also confers resistance to HF-induced weight gain and improvements in insulin sensitivity in mice [19]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective Follistatin-like 3 (fstl3), a natural inhibitor of members of the TGF-β family, increases during resistance training in human plasma. Fstl3 primarily binds myostatin and activin A, and thereby inhibits their functions. We hypothesize that blocking myostatin and activin A signalling through systemic fstl3 over-expression protects against diet-induced obesity and insulin resistance. Methods Fstl3 was over-expressed by DNA electrotransfer in tibialis anterior, quadriceps and gastrocnemius muscles in female C57BL/C mice, and the mice were subsequently randomized to chow or high-fat feeding. Body weight, food intake, fat accumulation by MR scanning, and glucose, insulin and glucagon tolerance were evaluated, as was the response in body weight and metabolic parameters to 24 hours fasting. Effects of fstl3 on pancreatic insulin and glucagon content, and pancreatic islet morphology were determined. Results Fstl3 over-expression reduced fat accumulation during high-fat feeding by 16%, and liver fat by 50%, as determined by MRI. No changes in body weight were observed, while the weight of the transfected muscles increased by 10%. No transcriptional changes were found in the subcutaneous adipose tissue. Fstl3 mice displayed improved insulin sensitivity and muscle insulin signalling. In contrast, glucose tolerance was impaired in high-fat fed fstl3 mice, which was explained by increased hepatic glucagon sensitivity and glucose output, as well as a decrease in the pancreatic insulin/glucagon ratio. Accordingly, fstl3 transfection improved counter-regulation to 24 hours fasting. Conclusion Fstl3 over-expression regulates insulin and glucagon sensitivities through increased muscular insulin action, as well as increased hepatic glucagon sensitivity and pancreatic glucagon content.
    Metabolism 10/2014; 64(2). DOI:10.1016/j.metabol.2014.10.007 · 3.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Myostatin (growth differentiation factor-8; GDF-8) is a potent negative regulator of muscle development affecting both proliferation and differentiation. Myostatin has been reported to enhance the release of cytokines, including TNF-α (a pro-inflammatory cytokine involved in implantation). In the human placenta, myostatin production is negatively correlated with gestational age and has been implicated in the control of glucose uptake. Preliminary data indicate its expression is primarily localized to cytotrophoblast and syncytiotrophoblast. The role of myostatin in the placenta, however, remains to be fully elucidated. We speculate that myostatin is key regulator that contributes to placentation and the regulation of placental function throughout pregnancy.
    Placenta 07/2012; 33(11):902-7. DOI:10.1016/j.placenta.2012.06.021 · 3.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: To assess the association between abdominal aortic calcification (AAC) and serum levels of myostatin, a negative regulator of skeletal muscle mass, which has been implicated in the development of atherosclerotic lesions in mice. DESIGN AND PATIENTS: We assessed AAC semiquantitatively from the lateral spine scans obtained using dual energy X-ray absorptiometry in 1071 men aged 20 to 87. Serum myostatin levels were measured by an immunoassay that detects all myostatin forms. RESULTS: Total myostatin serum levels did not differ between men with or without self-reported ischemic heart disease, hypertension, or diabetes mellitus. Total serum myostatin levels were higher in men with higher serum calcium levels and lower in men with higher serum concentrations of highly sensitive C-reactive protein. Men with AAC had lower myostatin levels compared with men without AAC. Prevalence of AAC (AAC score>0) was lower in the highest myostatin quartile compared with the three lower quartiles (p<0.05). After adjustment for confounders, odds of AAC (AAC score>0) were lower (OR=0.62, 95%CI: 0.45-0.85, p<0.005) for the fourth myostatin quartile vs. the three lower quartiles combined. In the sub-analysis of 745 men aged ≥60, the results were similar: AAC prevalence was lower in the highest myostatin quartile compared with the three lower quartiles combined (OR=0.54, 95%CI: 0.38, 0.78; p<0.001). CONCLUSIONS: In older men, total myostatin serum levels are inversely correlated with AAC. Further studies are needed to investigate mechanisms underlying this association and to assess utility of myostatin as a cardiovascular marker.
    European Journal of Endocrinology 09/2012; DOI:10.1530/EJE-12-0512 · 3.69 Impact Factor
Show more